Latest

Emcure Pharmaceuticals has received Income-tax Department orders imposing aggregate penalties of Rs. 57,73,96,732 for financial years 2014-15 through 2020-21. The company said it is evaluating legal remedies, including an appeal before the Appellate Authority.

Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company.

The Dispute Resolution Panel-2 did not accept most of DIC India’s objections to a draft assessment order involving an upward transfer-pricing adjustment of INR 3,84,17,653 for Assessment Year 2023-24. It directed the Assessing Officer to incorporate its findings in the final order; the company said it will evaluate that order and take appropriate action once received.